These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 15262461)
1. Results of a naturalistic study of treatment options: switching atypical antipsychotic drugs or augmenting with valproate. Cramer JA; Sernyak M Clin Ther; 2004 Jun; 26(6):905-14. PubMed ID: 15262461 [TBL] [Abstract][Full Text] [Related]
2. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis. Moisan J; Grégoire JP Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549 [TBL] [Abstract][Full Text] [Related]
3. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. Gianfrancesco F; Pesa J; Wang RH J Manag Care Pharm; 2005 Apr; 11(3):220-30. PubMed ID: 15804206 [TBL] [Abstract][Full Text] [Related]
4. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. Faries D; Ascher-Svanum H; Zhu B; Correll C; Kane J BMC Psychiatry; 2005 May; 5():26. PubMed ID: 15921508 [TBL] [Abstract][Full Text] [Related]
5. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone. Jing Y; Kim E; You M; Pikalov A; Tran QV J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195 [TBL] [Abstract][Full Text] [Related]
6. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder. Hassan M; Madhavan SS; Kalsekar ID; Makela EH; Rajagopalan K; Islam S; Kavookjian J; Miller LA Ann Pharmacother; 2007 Nov; 41(11):1812-8. PubMed ID: 17925501 [TBL] [Abstract][Full Text] [Related]
7. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. Schneider LS; Tariot PN; Dagerman KS; Davis SM; Hsiao JK; Ismail MS; Lebowitz BD; Lyketsos CG; Ryan JM; Stroup TS; Sultzer DL; Weintraub D; Lieberman JA; N Engl J Med; 2006 Oct; 355(15):1525-38. PubMed ID: 17035647 [TBL] [Abstract][Full Text] [Related]
9. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206 [TBL] [Abstract][Full Text] [Related]
10. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I; J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069 [TBL] [Abstract][Full Text] [Related]
12. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. Layton D; Harris S; Wilton LV; Shakir SA J Psychopharmacol; 2005 Sep; 19(5):473-82. PubMed ID: 16166184 [TBL] [Abstract][Full Text] [Related]
14. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618 [TBL] [Abstract][Full Text] [Related]
15. One-year rehospitalization rates of patients with first-episode bipolar mania receiving lithium or valproate and adjunctive atypical antipsychotics. Woo YS; Bahk WM; Jung YE; Jeong JH; Lee HB; Won SH; Lee KH; Jon DI; Yoon BH; Kim MD; Min KJ Psychiatry Clin Neurosci; 2014 Jun; 68(6):418-24. PubMed ID: 24506520 [TBL] [Abstract][Full Text] [Related]
16. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia. Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032 [TBL] [Abstract][Full Text] [Related]
17. Quetiapine versus other atypical antipsychotics for schizophrenia. Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315 [TBL] [Abstract][Full Text] [Related]
18. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. Gianfrancesco FD; Rajagopalan K; Sajatovic M; Wang RH J Clin Psychiatry; 2006 Feb; 67(2):222-32. PubMed ID: 16566617 [TBL] [Abstract][Full Text] [Related]
19. Mortality risk and mood stabilizers in bipolar disorder: a propensity-score-weighted population-based cohort study in 2002-2018. Chan JKN; Wong CSM; Fang CZ; Hung SC; Lo HKY; Chang WC Epidemiol Psychiatr Sci; 2024 May; 33():e31. PubMed ID: 38779809 [TBL] [Abstract][Full Text] [Related]
20. Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study. Chatterjee S; Chen H; Johnson ML; Aparasu RR Am J Geriatr Pharmacother; 2012 Apr; 10(2):83-94. PubMed ID: 22306198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]